Streamlining cardiovascular clinical trials to improve efficiency and generalisability
暂无分享,去创建一个
Deepak L. Bhatt | D. Madigan | M. Pfeffer | Y. Rosenberg | L. Lund | F. Zannad | D. Bonds | R. Temple | J. Borer | A. Maggioni | C. Meyers | T. Simon | W. G. Stough | L. Fiore | Andrew Zalewski | G. Calvo-rojas | N. Zariffa | N. Zariffa
[1] Rachael Williams,et al. Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect , 2018, BMJ Open Respiratory Research.
[2] E. Perucca. From clinical trials of antiepileptic drugs to treatment , 2018, Epilepsia open.
[3] Adam Cohen,et al. Improving public health by improving clinical trial guidelines and their application , 2017, European heart journal.
[4] E. Antman,et al. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.
[5] Catherine Harvey,et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. , 2016, The New England journal of medicine.
[6] L. Wallentin,et al. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). , 2016, American heart journal.
[7] M. Landray,et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. , 2016, European heart journal.
[8] Sean M. O'Brien,et al. ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and The Society of Thoracic Surgeons , 2015, Circulation. Cardiovascular quality and outcomes.
[9] Russell L. Rothman,et al. The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm , 2015, Annals of Internal Medicine.
[10] R. Califf,et al. The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. , 2015, American heart journal.
[11] Christopher B. Granger,et al. Registry-based randomized clinical trials—a new clinical trial paradigm , 2015, Nature Reviews Cardiology.
[12] Sunil V. Rao,et al. Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.
[13] C. Petrini. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview. , 2014, Annali dell'Istituto superiore di sanita.
[14] Chris Tachibana,et al. A guide to research partnerships for pragmatic clinical trials , 2014, BMJ : British Medical Journal.
[15] M. Lauer. Commentary on Vickers , 2014, Clinical trials.
[16] Taghrid Obied,et al. Oversight of clinical investigations- A risk based approach to monitoring , 2014 .
[17] Katie Brittain,et al. The effectiveness of collaborative care for people with memory problems in primary care: results of the CAREDEM case management modelling and feasibility study. , 2014, Health technology assessment.
[18] Brian J. McCourt,et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. , 2014, JACC. Cardiovascular interventions.
[19] Joy Adamson,et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. , 2014, Health technology assessment.
[20] T. Beauchamp,et al. Informed consent for comparative effectiveness trials. , 2014, The New England journal of medicine.
[21] Francis S. Collins,et al. PCORnet: turning a dream into reality , 2014, J. Am. Medical Informatics Assoc..
[22] Richard Platt,et al. Launching PCORnet, a national patient-centered clinical research network , 2014, Journal of the American Medical Informatics Association : JAMIA.
[23] M. Lauer,et al. The imperative of overcoming barriers to the conduct of large, simple trials. , 2014, JAMA.
[24] Michael S Lauer,et al. Eliminating the "expensive" adjective for clinical trials. , 2014, American heart journal.
[25] A. Woodcock,et al. Obtaining real-world evidence: the Salford Lung Study , 2014, Thorax.
[26] L. Svensson,et al. DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. , 2014, American heart journal.
[27] J. McMurray,et al. Large streamlined trials in cardiovascular disease. , 2014, European heart journal.
[28] T. Beauchamp,et al. Informed consent, comparative effectiveness, and learning health care. , 2014, The New England journal of medicine.
[29] Rustam Al-Shahi Salman,et al. Increasing value and reducing waste in biomedical research regulation and management , 2014, The Lancet.
[30] R. Califf,et al. Embedding cardiovascular research into practice. , 2013, JAMA.
[31] David Erlinge,et al. Thrombus aspiration during ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.
[32] Ralph B D'Agostino,et al. The randomized registry trial--the next disruptive technology in clinical research? , 2013, The New England journal of medicine.
[33] Mitchell W Krucoff,et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). , 2013, American heart journal.
[34] T. Puglisi. Reform within the common rule? Commentary. , 2013, The Hastings Center report.
[35] C. Grady,et al. Making the transition to a learning health care system. Commentary. , 2013, The Hastings Center report.
[36] R. Platt,et al. Evaluation as part of operations: reconciling the common rule and continuous improvement. Commentary. , 2013, The Hastings Center report.
[37] H. Krumholz,et al. Ethical oversight: serving the best interests of patients. Commentary. , 2013, The Hastings Center report.
[38] J. Menikoff. The unbelievable rightness of being in clinical trials. Commentary. , 2013, The Hastings Center report.
[39] S. Eckstein. The Oxford Textbook of Clinical Research Ethics , 2012 .
[40] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[41] Deepak L. Bhatt,et al. Advancing the care of cardiac patients using registry data: going where randomized clinical trials dare not. , 2010, JAMA.
[42] Ezekiel J. Emanuel,et al. The Oxford Textbook of Clinical Research Ethics , 2008 .
[43] S J Pocock,et al. Randomized trials or observational tribulations? , 2000, The New England journal of medicine.
[44] Robert Kevin Grigsby,et al. Federal Policy for the Protection of Human Subjects , 1993, Research on social work practice.
[45] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[46] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[47] Y. Ohtsuki,et al. ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.
[48] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[49] J. Salerno. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). , 1986, Lancet.
[50] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .